293 related articles for article (PubMed ID: 20514078)
1. Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective.
Li JL; Wang XD; Chen SY; Liu LS; Fu Q; Chen X; Teng LC; Wang CX; Huang M
Pharmacogenomics J; 2011 Aug; 11(4):300-6. PubMed ID: 20514078
[TBL] [Abstract][Full Text] [Related]
2. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
Niioka T; Satoh S; Kagaya H; Numakura K; Inoue T; Saito M; Narita S; Tsuchiya N; Habuchi T; Miura M
Transplantation; 2012 Nov; 94(10):1013-9. PubMed ID: 23073468
[TBL] [Abstract][Full Text] [Related]
3. Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism--a prospective, randomized, controlled study.
Chen SY; Li JL; Meng FH; Wang XD; Liu T; Li J; Liu LS; Fu Q; Huang M; Wang CX
Clin Transplant; 2013; 27(3):E272-81. PubMed ID: 23432535
[TBL] [Abstract][Full Text] [Related]
4. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
[TBL] [Abstract][Full Text] [Related]
5. Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers.
Tang HL; Xie HG; Yao Y; Hu YF
Pharmacogenet Genomics; 2011 Nov; 21(11):713-20. PubMed ID: 21886016
[TBL] [Abstract][Full Text] [Related]
6. Optimization of initial tacrolimus dose using pharmacogenetic testing.
Thervet E; Loriot MA; Barbier S; Buchler M; Ficheux M; Choukroun G; Toupance O; Touchard G; Alberti C; Le Pogamp P; Moulin B; Le Meur Y; Heng AE; Subra JF; Beaune P; Legendre C
Clin Pharmacol Ther; 2010 Jun; 87(6):721-6. PubMed ID: 20393454
[TBL] [Abstract][Full Text] [Related]
7. CYP3A5 genotype had no impact on intrapatient variability of tacrolimus clearance in renal transplant recipients.
Spierings N; Holt DW; MacPhee IA
Ther Drug Monit; 2013 Jun; 35(3):328-31. PubMed ID: 23666583
[TBL] [Abstract][Full Text] [Related]
8. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
[TBL] [Abstract][Full Text] [Related]
9. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
[TBL] [Abstract][Full Text] [Related]
10. The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients.
de Jonge H; Metalidis C; Naesens M; Lambrechts D; Kuypers DR
Pharmacogenomics; 2011 Sep; 12(9):1281-91. PubMed ID: 21770725
[TBL] [Abstract][Full Text] [Related]
11. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients.
Press RR; Ploeger BA; den Hartigh J; van der Straaten T; van Pelt J; Danhof M; de Fijter JW; Guchelaar HJ
Ther Drug Monit; 2009 Apr; 31(2):187-97. PubMed ID: 19258929
[TBL] [Abstract][Full Text] [Related]
12. The effect of CYP3A5 polymorphisms on the pharmacokinetics of tacrolimus in adolescent kidney transplant recipients.
Tirelli S; Ferraresso M; Ghio L; Meregalli E; Martina V; Belingheri M; Mattiello C; Torresani E; Edefonti A
Med Sci Monit; 2008 May; 14(5):CR251-254. PubMed ID: 18443548
[TBL] [Abstract][Full Text] [Related]
13. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients.
Loh PT; Lou HX; Zhao Y; Chin YM; Vathsala A
Transplant Proc; 2008 Jun; 40(5):1690-5. PubMed ID: 18589174
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose.
Bergmann TK; Hennig S; Barraclough KA; Isbel NM; Staatz CE
Ther Drug Monit; 2014 Feb; 36(1):62-70. PubMed ID: 24089074
[TBL] [Abstract][Full Text] [Related]
15. Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus.
Chen JS; Li LS; Cheng DR; Ji SM; Sun QQ; Cheng Z; Wen JQ; Sha GZ; Liu ZH
Transplant Proc; 2009 Jun; 41(5):1557-61. PubMed ID: 19545678
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients.
Santoro A; Felipe CR; Tedesco-Silva H; Medina-Pestana JO; Struchiner CJ; Ojopi EB; Suarez-Kurtz G
Pharmacogenomics; 2011 Sep; 12(9):1293-303. PubMed ID: 21806386
[TBL] [Abstract][Full Text] [Related]
17. CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation.
Glowacki F; Lionet A; Buob D; Labalette M; Allorge D; Provôt F; Hazzan M; Noël C; Broly F; Cauffiez C
Nephrol Dial Transplant; 2011 Sep; 26(9):3046-50. PubMed ID: 21677300
[TBL] [Abstract][Full Text] [Related]
18. Combinational Effect of CYP3A5 and MDR-1 Polymorphisms on Tacrolimus Pharmacokinetics in Liver Transplant Patients.
Buendía JA; Otamendi E; Kravetz MC; Cairo F; Ruf A; de Davila M; Powazniak Y; Nafissi J; Lazarowski A; Bramuglia G; Villamil F
Exp Clin Transplant; 2015 Oct; 13(5):441-8. PubMed ID: 26450467
[TBL] [Abstract][Full Text] [Related]
19. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
Nair SS; Sarasamma S; Gracious N; George J; Anish TS; Radhakrishnan R
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154
[TBL] [Abstract][Full Text] [Related]
20. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.
Thervet E; Anglicheau D; King B; Schlageter MH; Cassinat B; Beaune P; Legendre C; Daly AK
Transplantation; 2003 Oct; 76(8):1233-5. PubMed ID: 14578760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]